Dr. Karen Fink, MD, PhD
Claim this profileNeuro-Oncology Associates
Studies Glioblastoma
Studies Astrocytoma
6 reported clinical trials
12 drugs studied
Area of expertise
1Glioblastoma
MET positive
MET negative
IDH positive
2Astrocytoma
Affiliated Hospitals
Clinical Trials Karen Fink, MD, PhD is currently running
ONC201
for Brain Tumor
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
Recruiting1 award Phase 3
GammaTile + Stupp Protocol
for Glioblastoma
This trial tests if adding GammaTile radiation therapy to standard treatment can improve outcomes for patients with newly diagnosed GBM. GammaTile delivers quick, direct radiation to the tumor, which may help control the tumor better and improve survival rates.
Recruiting3 awards Phase 46 criteria
More about Karen Fink, MD, PhD
Clinical Trial Related1 year of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Karen Fink, MD, PhD has experience with
- Lomustine
- Eflornithine
- Optune®
- Temozolomide
- AQ4N
- Radiotherapy
Breakdown of trials Karen Fink, MD, PhD has run
Glioblastoma
Anaplastic Astrocytoma
Mesial Temporal Sclerosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Karen Fink, MD, PhD specialize in?
Karen Fink, MD, PhD focuses on Glioblastoma and Astrocytoma. In particular, much of their work with Glioblastoma has involved MET positive patients, or patients who are MET negative.
Is Karen Fink, MD, PhD currently recruiting for clinical trials?
Yes, Karen Fink, MD, PhD is currently recruiting for 2 clinical trials in Dallas Texas. If you're interested in participating, you should apply.
Are there any treatments that Karen Fink, MD, PhD has studied deeply?
Yes, Karen Fink, MD, PhD has studied treatments such as Lomustine, Eflornithine, Optune®.
What is the best way to schedule an appointment with Karen Fink, MD, PhD?
Apply for one of the trials that Karen Fink, MD, PhD is conducting.
What is the office address of Karen Fink, MD, PhD?
The office of Karen Fink, MD, PhD is located at: Neuro-Oncology Associates, Dallas, Texas 75246 United States. This is the address for their practice at the Neuro-Oncology Associates.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.